Non-small cell lung cancer treatment-related bone marrow toxicities.

abstract：:Cancer vaccines have shown success in curing tumors in preclinical models. Accumulating evidence also supports their ability to induce immune responses in patients. In many cases, these responses correlate with improved clinical outcomes. However, cancer vaccines have not yet demonstrated their true potential in clini...

journal_title：Seminars in oncology

authors： Keenan BP,Jaffee EM

更新日期：2012-06-01 00:00:00

abstract：:The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

journal_title：Seminars in oncology

authors： Hainsworth JD

更新日期：1992-08-01 00:00:00

abstract：:Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent advances in oncologic therapies have resulted in improved cancer outcomes but also a new set of cardiovascular adverse effects. Common toxicities include left ventricular dysfunction/heart failure, hypertension, and myocardial ...

journal_title：Seminars in oncology

authors： Davis M,Witteles RM

更新日期：2013-04-01 00:00:00

abstract：:Solid malignancies often exhibit high interstitial fluid pressure (IFP), which causes poor uptake of anticancer drugs. While there are several mechanisms that regulate IFP in tumors, activation of platelet-derived growth factor receptor, which is expressed in various cell types within the tumor microenvironment, has b...

journal_title：Seminars in oncology

authors： Pietras K

更新日期：2004-04-01 00:00:00

abstract：:Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...

journal_title：Seminars in oncology

authors： Foss F

更新日期：2006-02-01 00:00:00

abstract：:In spite of the chemosensitivity seen with the initial treatment of malignant lymphoid disorders, relapse is common and death most often occurs as a result of disease progression. This is related to a multitude of resistance mechanisms associated with the various lymphoproliferative disorders. As a result, therapies t...

journal_title：Seminars in oncology

authors： Byrd JC,Grever MR,Waselenko JK,Willis CR,Park K,Goodrich A,Lucas MA,Shinn C,Flinn IW

更新日期：2000-04-01 00:00:00

abstract：:Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

journal_title：Seminars in oncology

authors： Zinzani PL

更新日期：2005-02-01 00:00:00

abstract：:The clinical development of the recombinant alpha interferons has provided a prototype for the clinical development of biological compounds. With over 5,000 patients now treated with these compounds, some general principles have emerged that have wider implications for phase I-II strategies for testing other biologica...

journal_title：Seminars in oncology

authors： Spiegel RJ

更新日期：1987-06-01 00:00:00

abstract：:Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled ...

journal_title：Seminars in oncology

authors： Wu PK,Park JI

更新日期：2015-12-01 00:00:00

abstract：:Autoimmune complications are common in chronic lymphocytic leukemia (CLL), occurring in up to a quarter of all patients during the course of the illness. By far the most common manifestation is autoimmune hemolytic anemia (AIHA), followed by immune thrombocytopenia (ITP). It is not true to say that autoimmunity is con...

journal_title：Seminars in oncology

authors： Hamblin TJ

更新日期：2006-04-01 00:00:00

abstract：:Recently, a randomized study conducted by the Gynecologic Oncology Group (GOG 111) demonstrated that, given by a 24-hour infusion, the combination of cisplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is superior to combination cisplatin/cyclophosphamide in previously untreated patients with...

journal_title：Seminars in oncology

authors： Meerpohl HG,du Bois A,Luck HJ,Kühnle H,Möbus V,Kreienberg R,Bauknecht T,Köchli O,Bochtler H,Diergarten K

更新日期：1997-02-01 00:00:00

abstract：:A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...

journal_title：Seminars in oncology

authors： Ruit JB,Löwenberg B,Hagenbeek A,Verhoef GE,Wielenga JJ,Michiels J,Sizoo W

更新日期：1990-12-01 00:00:00

abstract：:The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

journal_title：Seminars in oncology

authors： Fumoleau P

更新日期：2003-04-01 00:00:00

abstract：:The purpose of this pilot study was to determine the safety and feasibility of accelerated fractionation (via concomitant boost) radiotherapy (XRT) with concurrent carboplatin/paclitaxel chemotherapy for locally advanced stage III non-small cell lung carcinoma. Radiotherapy consisted of 3-dimensional conformal techniq...

journal_title：Seminars in oncology

authors： Machtay M,Washam C,Devine P

更新日期：2005-04-01 00:00:00

abstract：:The natural history of squamous cell head and neck cancer is well understood. Locoregional approaches to salvage therapy for this disease have curative potential, primarily because distant metastases are uncommon. Before proceeding with salvage treatment, however, clinicians should identify the extent of disease and d...

journal_title：Seminars in oncology

authors： Adelstein DJ

更新日期：1994-08-01 00:00:00

abstract：:The combination of paclitaxel and carboplatin is now established as the standard first-line chemotherapy regimen for advanced ovarian cancer. Ways in which this standard therapy can be further improved are being investigated, and several approaches have been taken. One approach is to integrate a different cytotoxic ag...

journal_title：Seminars in oncology

authors： Thigpen T

更新日期：2006-04-01 00:00:00

abstract：:Adjuvant chemotherapy has a real but modest impact on the disease-free and overall survival of patients with breast cancer. Recent attempts to improve its effectiveness have focused on dose intensity and new agents. Sequential therapy maximized dose intensity while limiting overlapping toxicity. Sequential therapy usi...

journal_title：Seminars in oncology

authors： Hudis C,Seidman A,Raptis G,Fennelly D,Gilewski T,Baselga J,Theodoulou M,Sklarin N,Moynahan M,Surbone A,Currie V,Lebwohl D,Uhlenhopp M,Crown J,Norton L

更新日期：1996-02-01 00:00:00

abstract：:For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

journal_title：Seminars in oncology

authors： Varadhachary GR,Hoff PM

更新日期：2005-12-01 00:00:00

abstract：:Two phase II trials of mitoxantrone in refractory malignant lymphoma have been conducted. In the first of these, mitoxantrone (5 mg/m2) was given weekly for 6 weeks, and in the second, 14 mg/m2 was administered every 3 weeks. The first trial was conducted by the Southeastern Cancer Study Group (SECSG), and the second ...

journal_title：Seminars in oncology

authors： Gams RA,Steinberg J,Posner L

更新日期：1984-09-01 00:00:00

abstract：:Vinorelbine, a vinca alkaloid, was the first drug in over 20 years to be approved by the Food and Drug Administration for treatment of advanced non-small cell lung cancer (NSCLC). The drug's nonhematologic toxicities are usually mild; its dose-limiting toxicity is neutropenia. Vinorelbine has been studied in many phas...

journal_title：Seminars in oncology

authors： Wozniak AJ

更新日期：1999-10-01 00:00:00

abstract：:Constitutive expression of interferons (IFNs) and activation of their signaling pathways have pivotal roles in host responses to malignant cells in the tumor microenvironment. IFNs are induced by the innate immune system and in tumors through stimulation of Toll-like receptors (TLRs) and through other signaling pathwa...

journal_title：Seminars in oncology

authors： Cheon H,Borden EC,Stark GR

更新日期：2014-04-01 00:00:00

abstract：:This study reports the effectiveness and side effects of intravenous ondansetron as a single-agent antiemetic therapy for patients receiving emetogenic cancer chemotherapy under a compassionate-use program for patients not enrolled in controlled clinical trials. Patients were > or = 7 years old and had uncontrolled na...

journal_title：Seminars in oncology

authors： Berry WR,House KW,Lee JT,Plagge PB,Meshad MW,Grapski R

更新日期：1992-12-01 00:00:00

abstract：:Eighteen percent of incident malignancies in the United States are a second (or subsequent) cancer. Second primary neoplasms (SPNs), particularly solid tumors, are a major cause of mortality and serious morbidity among cancer survivors successfully cured of their first cancer. Multiple etiologies may lead to a cancer ...

journal_title：Seminars in oncology

authors： Oeffinger KC,Baxi SS,Novetsky Friedman D,Moskowitz CS

更新日期：2013-12-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel-based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubic...

journal_title：Seminars in oncology

authors： Kennedy MJ,Donehower RC,Rowinsky EK

更新日期：1995-08-01 00:00:00

abstract：:Almost 125 years after the first documented case, pulmonary metastasectomy is still poorly understood. No other organ is subject to the wide histologic variety of metastatic insults, and this fact has complicated a complete exposition of when pulmonary metastasectomy may be beneficial. Many physicians still consider p...

journal_title：Seminars in oncology

authors： Sternberg DI,Sonett JR

更新日期：2007-06-01 00:00:00

abstract：:Spirituality can exert a tremendous impact on ones health and promote recovery from trauma and illness, including cancer. Throughout the history of mankind, spirituality and religion have played a major role in healing a variety of physical and mental illnesses. Cancer is one of the most devastating illnesses, as it a...

journal_title：Seminars in oncology

authors： Torosian MH,Biddle VR

更新日期：2005-04-01 00:00:00

abstract：:As continuous ambulatory peritoneal dialysis becomes more popular, the science of catheter selection, insertion, and maintenance becomes increasingly necessary. The proper use of and possible complications associated with several currently used catheters are discussed. The pros and cons of single- and double-cuff cath...

journal_title：Seminars in oncology

authors： Twardowski ZJ

更新日期：1985-09-01 00:00:00

abstract：:Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Adm...

journal_title：Seminars in oncology

authors： Steensma DP

更新日期：2011-10-01 00:00:00

abstract：:Complementary and alternative therapies are used with increasing frequency in men with prostate cancer. However, little is known about the efficacy of such therapies for this cancer. While epidemiological data support the association between intake of certain micronutrients with development of prostate cancer, there e...

journal_title：Seminars in oncology

authors： Oh WK,Small EJ

更新日期：2002-12-01 00:00:00

abstract：:Combination therapy consisting of Lipiodol (Laboratoire Guerbet, Villepinte, France) containing styrene maleic acid neocarzinostatin and transcatheter arterial embolization (L-TAE) has been an important conservative therapy for hepatocellular carcinoma (HCC). We examined the clinical and pathologic characteristics of ...

journal_title：Seminars in oncology

authors： Kenji J,Hyodo I,Tanimizu M,Tanada M,Nishikawa Y,Hosokawa Y,Mandai K,Moriwaki S

更新日期：1997-04-01 00:00:00